Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growin...
09 Octobre 2018 - 3:05PM
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its
2018 partnership with the World Thrombosis Day campaign to help
raise global awareness of thrombosis. Observed annually on October
13, World Thrombosis Day is led by the International Society on
Thrombosis and Haemostasis (ISTH), which has mobilized more than
1,500 partner organizations worldwide this year to shine a
spotlight on the burden of arterial or venous thrombosis – the
potentially life-threatening formation of blood clots in an artery
or vein – and conditions caused by it.
Atrial fibrillation (AFib) and venous
thromboembolism (VTE) are two major causes of thrombosis that
affect millions of people worldwide. AFib, or arrhythmia, is a
common type of irregular heartbeat that can lead to a clot forming
in the chamber of the heart and traveling to the brain. Although
less common than VTE, AFib increases the individual risk of stroke
and accounts for approximately 15 percent of the 15 million strokes
that occur worldwide every year.
VTE refers collectively to deep vein thrombosis
(DVT), a clot in a deep vein, usually in the leg, groin or arm; or
a pulmonary embolism (PE), an often-fatal condition that occurs
when a DVT breaks free from a vein wall and travels to the lungs,
blocking some or all of the blood supply. In the United States
alone, up to 300,000 deaths per year, or 800 deaths per day, are
attributable to a VTE. VTE risk is particularly high among the more
than 8 million patients hospitalized annually for heart failure,
respiratory failure, acute infection, stroke and other “acutely ill
medical” conditions.
“VTE is the leading cause of preventable
hospital death – ahead of pneumonia and infection – with more than
half of all VTE cases occurring within the first 40 days following
hospital admission,” said John Curnutte, M.D., Ph.D., executive
vice president, research and development at Portola. “We are proud
to support the World Thrombosis Day campaign’s efforts to raise
awareness of thrombosis; particularly the risk of VTE and the
importance of ensuring that protocols are in place to identify
patients at risk and to initiate treatment when needed for this
preventable yet potentially fatal condition.”
“Thrombosis is the leading cause of the world’s
top three cardiovascular killers – heart attack, stroke and VTE,”
said Gary Raskob, Ph.D., Chairman of the World Thrombosis Day
Steering Committee for the International Society on Thrombosis and
Haemostasis. “We are proud to partner with Portola on the World
Thrombosis Day movement to raise awareness of VTE as a significant
and growing public health crisis, and to encourage healthcare
organizations to review, update or establish protocols that
proactively assess VTE risk for the full duration of its potential
impact, beginning at hospital admission.”
About World Thrombosis DayNow
in its fifth year, World Thrombosis Day is a global movement
observed annually on October 13 and led by ISTH. More than 1,500
organizations representing more than 90 countries worldwide will
join together this year to highlight thrombosis as an urgent,
growing and underappreciated health condition, and encourage
healthcare professionals, key decision makers and the public to
know the risk factors, signs/symptoms and appropriate
prevention.
World Thrombosis Day’s mission supports the
World Health Assembly's global target of reducing premature deaths
by non-communicable disease by 25 percent by 2025, as well as the
World Health Organization’s (WHO) global action plan for the
prevention and control of non-communicable diseases in the
2013-2020 timeframe. Portola Pharmaceuticals is one of many proud
sponsors of World Thrombosis Day 2018. Visit
www.worldthrombosisday.org for more information.
About the ISTHFounded in 1969,
the International Society on Thrombosis and Haemostasis (ISTH) is
the leading worldwide not-for-profit organization dedicated to
advancing the understanding, prevention, diagnosis and treatment of
thrombotic and bleeding disorders. The ISTH is an international
membership organization with nearly 4,000 clinicians, researchers
and educators working together to improve the lives of patients in
more than 94 countries around the world. Among its highly regarded
activities and initiatives are education and standardization
programs, research activities, meetings and conferences,
peer-reviewed publications and expert committees. Visit ISTH online
at www.isth.org.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are Andexxa®
[coagulation factor Xa (recombinant), inactivated-zhzo], the first
and only antidote for patients treated with rivaroxaban and
apixaban when reversal of anticoagulation is needed due to
life-threatening or uncontrolled bleeding, and
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor for the prevention of VTE in adult patients
hospitalized for an acute medical illness. The company also is
advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of
hematologic cancers.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
ir@portola.com
Media Contact:Patrick RyanPure
Communications pryan@purecommunications.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024